MUMBAI, Sept. 9 (Xinhua) — An Indian company continues with its clinical trials for COVID-19 vaccine even as its partner AstraZeneca took a pause to the global trials of the COVID-19 vaccine candidate developed by the University of Oxford.
“The Indian trials are continuing and we have faced no issues at all,” said Serum Institute, the World’s largest vaccine manufacturer, on Wednesday.
The Indian company, which manufactures and sells over 1.5 billion doses globally and has been contracted by the British-Swedish pharmaceutical firm AstraZeneca and University of Oxford to manufacture the proposed vaccine for low- and middle-income countries said that it can not comment on reports of AstraZeneca pausing the trials in Britain, other than that they have been paused for review and shall restart soon.
AstraZeneca late on Tuesday had announced a pause to the global trials of the COVID-19 vaccine candidate after one participant developed an unexplained illness in Britain.
The adverse event seen in the case in Britain has not been noted in any of the Indian participants so far. However, it is likely to be taken up by a safety expert group which will review information collected from the first set of participants in the human clinical trials in India, said the Indian Express newspaper report.
In July, Serum Institute received approval to conduct human clinical trials from the Indian drug regulator.
The number of COVID-19 cases in India rose by 89,706 on Wednesday, taking the total tally to 4,370,128 with the total deaths standing at 73,890, according to the federal health ministry. Enditem